News
ATOS
1.500
+0.67%
0.010
Weekly Report: what happened at ATOS last week (0415-0419)?
Weekly Report · 2d ago
Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatment
TipRanks · 04/15 16:05
ATOSSA THERAPEUTICS: UNDER TERMS OF STUDY, CO WILL CONDUCT STUDY WITH ATOSSA & ELI LILLY AND CO EACH RESPONSIBLE FOR SUPPLYING RESPECTIVE STUDY DRUGS
Reuters · 04/15 12:30
ATOSSA THERAPEUTICS AND QUANTUM LEAP HEALTHCARE ANNOUNCE I-SPY 2 CLINICAL TRIAL TO EVALUATE (Z)-ENDOXIFEN IN COMBINATION WITH ABEMACICLIB (VERZENIO®) IN WOMEN WITH ER+/HER2- BREAST CANCER
Reuters · 04/15 12:30
Weekly Report: what happened at ATOS last week (0408-0412)?
Weekly Report · 04/15 10:40
Atossa Therapeutics Poised for Growth with Promising Breast Cancer Treatment
TipRanks · 04/10 19:05
Atossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy Potential
TipRanks · 04/10 10:26
Atossa stock climbs 11% on breast cancer drug data
Atossa stock climbs 11% on breast cancer drug data. Atossa Therapeutics reported encouraging data from a Phase 2 study of its drug for breast cancer. The drug is being tested as a treatment for premenopausal women with Grade 1 or 2 cancer.
Seeking Alpha · 04/09 18:37
Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Atossa is a clinical stage biopharmaceutical company with a focus on breast cancer. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 breast cancer .
Benzinga · 04/09 16:00
ATOSSA THERAPEUTICS PRESENTS DATA FROM 40MG COHORT OF PHASE 2 EVANGELINE CLINICAL TRIAL SHOWING 100% DISEASE CONTROL RATE AFTER 24-WEEKS OF TREATMENT WITH (Z)-ENDOXIFEN
Reuters · 04/09 15:59
Weekly Report: what happened at ATOS last week (0401-0405)?
Weekly Report · 04/08 10:43
ATOS, SMR and EIGR are among pre market gainers
On the Move ATOS, SMR and EIGR are among pre market gainers. GCT Semiconductor Holding (GCTS) and MediaCo Holding (MDIA) are among the biggest pre market losers. Atossa Therapeutics, Inc. Provides Pemgarda 2024 net product revenue guidance.
Seeking Alpha · 04/05 12:34
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
TipRanks · 04/03 19:20
Navigating Choppy Waters: Atossa Therapeutics’ Struggle with Compliance Costs and Business Performance
TipRanks · 04/03 06:01
Atossa Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/02 12:47
Atossa Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 04/02 12:47
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Maintains $4 Price Target
Benzinga · 04/02 12:36
Optimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer Therapy
TipRanks · 04/02 10:26
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
Atossa Therapeutics reported earnings per share of -6 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -5 cents. Atossa reported results for the last quarter of 2013.
Investorplace · 04/02 02:53
Atossa Therapeutics GAAP EPS of -$0.24 in-line
Seeking Alpha · 04/01 20:41
More
Webull provides a variety of real-time ATOS stock news. You can receive the latest news about Atossa Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATOS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Company’s lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.